Eculizumab and ravulizumab are humanized monoclonal antibodies that bind to C5 [5,6] with established safety and efficacy in patients with PNH, aHUS, gMG, and AQP4-Ab+ NMOSD in several clinical trials [8–12]. Here, AQP4 is linked to paroxysmal nocturnal hemoglobinuria.